Merck & Co., Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent
Merck & Co., Inc. (MRK) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent of -$70.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent · last filed 2018-05-08
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2018-03-31 was -$70.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2017-09-30 was -$66.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2017-06-30 was -$143.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2017-03-31 was -$232.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 9 month |
|---|---|---|---|
| 2018-03-31 | -$70.00M 10-Q · filed 2018-05-08 | ||
| 2017-09-30 | -$66.00M 10-Q · filed 2017-11-07 | -$209.00M derived: sum of 2 quarters · filed 2017-11-07 | -$441.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$143.00M 10-Q · filed 2017-08-08 | -$375.00M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | -$232.00M 10-Q · filed 2018-05-08 | ||
| 2016-09-30 | -$74.00M 10-Q · filed 2017-11-07 | -$165.00M derived: sum of 2 quarters · filed 2017-11-07 | -$367.00M 10-Q · filed 2017-11-07 |
| 2016-06-30 | -$91.00M 10-Q · filed 2017-08-08 | -$293.00M 10-Q · filed 2017-08-08 | |
| 2016-03-31 | -$202.00M 10-Q · filed 2017-05-09 | ||
| 2015-09-30 | -$118.00M 10-Q · filed 2016-11-07 | -$294.00M derived: sum of 2 quarters · filed 2016-11-07 | -$42.00M 10-Q · filed 2016-11-07 |
| 2015-06-30 | -$176.00M 10-Q · filed 2016-08-08 | $76.00M 10-Q · filed 2016-08-08 | |
| 2015-03-31 | $252.00M 10-Q · filed 2016-05-09 | ||
| 2014-09-30 | $254.00M 10-Q · filed 2015-11-05 | $149.00M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |